Skip to main content
. 2013 Nov 11;8(11):e80437. doi: 10.1371/journal.pone.0080437

Table 1. Patient baseline characteristics.

Lenalidomide (n = 21) Lenalidomide plus cetuximab (n = 29)
Median age, years (range) 54 (38–75) 58 (31–70)
Sex Male 12 (57.1%) 16 (55.2%)
Female 9 (42.9%) 13 (44.8%)
ECOG PS score 0 10 (47.6%) 20 (69.0%)
1 10 (47.6%) 9 (31.0%)
2 1 (4.8%) 0
Concomitant steroids 7 (33%) 12 (41%)
Previous lines of systemic anticancer therapy 2 5 (23.8%) 9 (31.0%)
3 4 (19.0%) 6 (20.7%)
>3 12 (57.1%) 14 (48.2%)

ECOG PS, Eastern Cooperative Oncology Group performance status.